Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
People living with human immunodeficiency virus infection (HIV) have 2-4fold greater risk for
developing diabetes and heart disease than the general population. They need safe and
effective treatments that reduce the risk for developing diabetes and heart disease, and
improve their quality of life. This project will explore whether a new anti-diabetes
medication (Januvia) with a novel mechanism of action reduces inflammation, and improves
blood vessel function in HIV infected men and women with several risk factors for developing
cardiovascular disease.